| DB ID | MyCo_1581 |
| Title | Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation |
| Year | 2001 |
| PMID | 11238098 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | Prolonged Neutropenic Patients and Stem Cell Transplantation recipients |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Blood |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Belgium |
| Cohort | From January 1997 through February 2000, serum GM levels were prospectively measured in a consecutive series of adult patients with hematological disorders who were at risk for developing IA. Eligible patients were (1) receiving chemotherapy with an expected duration of neutropenia (less than 500 cells per L) of at least 10 days because of de novo or relapsed acute leukemia (AL), chronic myeloid leukemia (CML) undergoing AL-like induction, lymphoblastic non-Hodgkin lymphoma, or high-risk myelodysplasia (refractory anemia with excess blasts [RAEB], RAEB in transformation [RAEBt], or acute myeloid leukemia [sAML]) or (2) undergoing allogeneic bone marrow or peripheral blood stem cell transplantation. We excluded those patients who were undergoing autologous transplantation, had aplastic anemia, or were less than 16 years of age. We collected 5 mL whole blood at least twice weekly, starting at admission, until death or discharge from hospital. |
| Cohort No. | 191 |
| Age Group | > 16 |
| P Value | None |
| Sensitivity | 0.897 |
| Specificity | 0.981 |
| Positive Predictive Value | 0.875 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive aspergillosis (IA) is an emerging opportunistic infection among many categories of immunocompromised hosts. The high mortality rate results partly from difficulties in establishing a reliable diagnosis, particularly in patients who receive cytoreductive or marrow-ablative therapy. Although gold diagnostic standards exist, they usually require invasive procedures to obtain specimens for histological examination and culture.4 Unfortunately, such aggressive procedures are often precluded by cytopenia or by the critical condition of these patients. Hence, definite diagnosis is infrequently established before death or before fungal proliferation becomes overwhelming and therapy may no longer be successful. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | ELISA Kit (Platelia Aspergillus; Sanofi Diagnostics Pasteur, Marnes-La-Coquette, France) |
| Assay Data | None |
| Validation Techniques used | ELISA, CT |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
